709 related articles for article (PubMed ID: 7522954)
21. CD16- CD56+ natural killer cells after bone marrow transplantation.
Jacobs R; Stoll M; Stratmann G; Leo R; Link H; Schmidt RE
Blood; 1992 Jun; 79(12):3239-44. PubMed ID: 1375847
[TBL] [Abstract][Full Text] [Related]
22. Differential expression of the interleukin 2 receptor beta (p75) chain on human peripheral blood natural killer subsets.
Nishikawa K; Saito S; Morii T; Kato Y; Narita N; Ichijo M; Ohashi Y; Takeshita T; Sugamura K
Int Immunol; 1990; 2(6):481-6. PubMed ID: 1707657
[TBL] [Abstract][Full Text] [Related]
23. Production of granulocyte/macrophage-colony-stimulating factor by human natural killer cells. Modulation by the p75 subunit of the interleukin 2 receptor and by the CD2 receptor.
Levitt LJ; Nagler A; Lee F; Abrams J; Shatsky M; Thompson D
J Clin Invest; 1991 Jul; 88(1):67-75. PubMed ID: 1676038
[TBL] [Abstract][Full Text] [Related]
24. Accumulation of CD16-CD56+ natural killer cells with high affinity interleukin 2 receptors in human early pregnancy decidua.
Nishikawa K; Saito S; Morii T; Hamada K; Ako H; Narita N; Ichijo M; Kurahayashi M; Sugamura K
Int Immunol; 1991 Aug; 3(8):743-50. PubMed ID: 1716974
[TBL] [Abstract][Full Text] [Related]
25. Generation propagation, and targeting of human CD4+ helper/killer T cells induced by anti-CD3 monoclonal antibody plus recombinant IL-2. An efficient strategy for adoptive tumor immunotherapy.
Nishimura T; Nakamura Y; Takeuchi Y; Tokuda Y; Iwasawa M; Kawasaki A; Okumura K; Habu S
J Immunol; 1992 Jan; 148(1):285-91. PubMed ID: 1345787
[TBL] [Abstract][Full Text] [Related]
26. Activation of leukemic large granular lymphocytes by interleukin-2 via the p75 interleukin-2 receptor.
Yoon HJ; Sugamura K; Loughran TP
Leukemia; 1990 Dec; 4(12):848-50. PubMed ID: 2147047
[TBL] [Abstract][Full Text] [Related]
27. IL-12 is involved in the activation of CD3+ granular lymphocytes in patients with lymphoproliferative disease of granular lymphocytes.
Zambello R; Trentin L; Cassatella MA; Raimondi R; Cerutti A; Enthammer C; Facco M; Agostini C; Semenzato G
Br J Haematol; 1996 Feb; 92(2):308-14. PubMed ID: 8602990
[TBL] [Abstract][Full Text] [Related]
28. Natural killer cells activated by interleukin 2 treatment in vivo respond to interleukin 2 primarily through the p75 receptor and maintain the p55 (TAC) negative phenotype.
Weil-Hillman G; Voss SD; Fisch P; Schell K; Hank JA; Sosman JA; Sugamura K; Sondel PM
Cancer Res; 1990 May; 50(9):2683-91. PubMed ID: 1691679
[TBL] [Abstract][Full Text] [Related]
29. Activation via the CD3 and CD16 pathway mediates interleukin-2-dependent autocrine proliferation of granular lymphocytes in patients with granular lymphocyte proliferative disorders.
Hoshino S; Oshimi K; Teramura M; Mizoguchi H
Blood; 1991 Dec; 78(12):3232-40. PubMed ID: 1835892
[TBL] [Abstract][Full Text] [Related]
30. Low doses of rIL2 after autologous bone marrow transplantation induce a "prolonged" immunostimulation of NK compartment in high-grade non-Hodgkin's lymphomas.
Raspadori D; Lauria F; Ventura MA; Tazzari PL; Ferrini S; Miggiano MC; Rondelli D; Tura S
Ann Hematol; 1995 Oct; 71(4):175-9. PubMed ID: 7578523
[TBL] [Abstract][Full Text] [Related]
31. Role of LFA-1/ICAM-1 in interleukin-2-stimulated lymphocyte proliferation.
Vyth-Dreese FA; Dellemijn TA; Frijhoff A; van Kooyk Y; Figdor CG
Eur J Immunol; 1993 Dec; 23(12):3292-9. PubMed ID: 7903074
[TBL] [Abstract][Full Text] [Related]
32. In vivo activated cord blood lymphocytes express high affinity interleukin-2 receptor: evaluation of their responsiveness to in vitro stimulation with recombinant interleukin-2.
Montagna D; Moretta A; Marconi M; Mingrat G; Gasparoni A; Giarola M; Maccario R
Biol Neonate; 1992; 62(6):385-94. PubMed ID: 1472581
[TBL] [Abstract][Full Text] [Related]
33. Biological monitoring of low-dose interleukin 2 in humans: soluble interleukin 2 receptors, cytokines, and cell surface phenotypes.
Hänninen EL; Körfer A; Hadam M; Schneekloth C; Dallmann I; Menzel T; Kirchner H; Poliwoda H; Atzpodien J
Cancer Res; 1991 Dec; 51(23 Pt 1):6312-6. PubMed ID: 1933892
[TBL] [Abstract][Full Text] [Related]
34. Immunological changes in peripheral blood mononuclear cells of patients with metastatic renal cell carcinoma after low doses of subcutaneous immunotherapy with IFN-alpha-2b and IL-2.
Moltó L; Carballido J; Manzano L; Martinez-Martin B; Esquivel F; Chafer J; Olivier C; Alvarez-Mon M
J Immunother; 1999 May; 22(3):260-7. PubMed ID: 10335486
[TBL] [Abstract][Full Text] [Related]
35. Recombinant interleukin-2 and lymphokine-activated killer cells in renal cancer patients: I. Phenotypic and functional analysis of the peripheral blood mononuclear cells.
Fortis C; Ferrero E; Besana C; Biffi M; Heltai S; Galli L; Borri A; Schoenheit A; Rugarli C
Cancer Immunol Immunother; 1990; 32(3):161-6. PubMed ID: 2289209
[TBL] [Abstract][Full Text] [Related]
36. Immunogenicity of recombinant human interleukin-2: biological features and clinical relevance.
Hänninen EL; Knüver-Hopf J; Atzpodien J
Biotherapy; 1993; 6(4):251-61. PubMed ID: 7517168
[TBL] [Abstract][Full Text] [Related]
37. Interleukin-15 triggers the proliferation and cytotoxicity of granular lymphocytes in patients with lymphoproliferative disease of granular lymphocytes.
Zambello R; Facco M; Trentin L; Sancetta R; Tassinari C; Perin A; Milani A; Pizzolo G; Rodeghiero F; Agostini C; Meazza R; Ferrini S; Semenzato G
Blood; 1997 Jan; 89(1):201-11. PubMed ID: 8978293
[TBL] [Abstract][Full Text] [Related]
38. Purified human T cells stimulated with cross-linked anti-CD3 monoclonal antibody OKT3: rIL-1 is a co-stimulatory factor for CD4+CD29+CD45RA- T cells.
Panzer S; Geller RL; Bach FH
Scand J Immunol; 1990 Oct; 32(4):359-71. PubMed ID: 1700468
[TBL] [Abstract][Full Text] [Related]
39. Recombinant interleukin-2 treatment before and after autologous stem cell transplantation in hematologic malignancies: clinical and immunologic effects.
De Laurenzi A; Iudicone P; Zoli V; De Rosa L; Guglielmetti M; Pescarollo A; Papetti C; Pacilli L; Lapponi P; Petti N
J Hematother; 1995 Apr; 4(2):113-20. PubMed ID: 7633841
[TBL] [Abstract][Full Text] [Related]
40. In vitro responsiveness to interleukins and theophylline of CD16+, CD56- natural killer cells in a patient with chronic granular lymphocyte disorder.
Bayle C; Vitté-Mony I; Lang P; Pico J; Hercend T; Bertoglio J
Leukemia; 1992 May; 6(5):470-6. PubMed ID: 1375700
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
